Literature DB >> 1276000

Pharmacokinetics of pancuronium in patients with normal and impaired renal function.

K McLeod, M J Watson, M D Rawlins.   

Abstract

Plasma concentrations of pancuronium were measured using a fluorimetric method in six patients with normal renal function and seven patients in chronic renal failure. A tow-compartment open model was used in the pharmacokinetic analysis of the data. With this model, the clearance of pancuronium was found to be reduced significantly in the patients with renal failure, and in these individuals the volume of the central (distribution) compartment was increased significantly. The clinical implications of these findings are discussed.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1276000     DOI: 10.1093/bja/48.4.341

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  18 in total

Review 1.  Recent developments with muscles relaxants and their antagonists.

Authors:  R D Miller
Journal:  Can Anaesth Soc J       Date:  1979-03

Review 2.  Clinical pharmacokinetics of neuromuscular blocking drugs.

Authors:  S Agoston; R H Vandenbrom; J M Wierda
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

3.  Investigation of the cardiac effects of pancuronium, rocuronium, vecuronium, and mivacurium on the isolated rat atrium.

Authors:  Sinan Gursoy; Ihsan Bagcivan; Nedim Durmus; Kenan Kaygusuz; Iclal Ozdemir Kol; Cevdet Duger; Sahin Yildirim; Caner Mimaroglu
Journal:  Curr Ther Res Clin Exp       Date:  2011-10

4.  Ligated renal pedicles and duration of action of neostigmine and pyridostigmine.

Authors:  R D Miller; L Roderick
Journal:  Br J Pharmacol       Date:  1977-08       Impact factor: 8.739

5.  Clinical pharmacokinetics of muscle relaxants.

Authors:  L B Wingard; D R Cook
Journal:  Clin Pharmacokinet       Date:  1977 Sep-Oct       Impact factor: 6.447

6.  Influence of impaired renal function on the disposition of [14C]fazadinium in the anaesthetized greyhound [proceedings].

Authors:  D R Bevan; J Caldwell; J D'Souza; R L Smith
Journal:  Br J Pharmacol       Date:  1978-11       Impact factor: 8.739

Review 7.  Influence of renal and hepatic function on pharmacodynamics and pharmacokinetics of non-depolarizing muscle relaxants.

Authors:  L H Booij
Journal:  Pharm Weekbl Sci       Date:  1987-04-24

8.  Clinical pharmacokinetics and pharmacodynamics of fazadinium in renal failure.

Authors:  D R Bevan; J D D'Souza; J M Rouse; J Caldwell; R L Smith
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

9.  Pharmacokinetics of pancuronium in patients undergoing coronary artery surgery with and without low dose dopamine.

Authors:  J M Wierda; P J van der Starre; A H Scaf; W D Kloppenburg; J H Proost; S Agoston
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

10.  Pharmacokinetics and pharmacodynamics of vecuronium bromide.

Authors:  T Nomura
Journal:  J Anesth       Date:  1992-01       Impact factor: 2.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.